These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes.
    Author: Lee BC, Lee HJ, Chung JH.
    Journal: Neurosci Lett; 2006 Dec 20; 410(2):141-5. PubMed ID: 17084528.
    Abstract:
    Peroxisome proliferator-activated receptor (PPAR)-gamma2 has important effects to insulin sensitivity, atherosclerosis, inflammation and endothelial cell function. Through these effects, PPAR-gamma2 might be involved with the ischemic stroke in type 2 diabetes. To determine the role of PPAR-gamma2 in genetic susceptibility to ischemic stroke in type 2 diabetes, we genotyped 302 ischemic stroke patients, 283 healthy controls and 141 type 2 diabetic patients without ischemic stroke (diabetes duration >10 years) for PPAR-gamma2 Pro12Ala polymorphism by polymerase chain reaction-restriction fragment length polymorphism methods. PPAR-gamma2 Pro/Ala genotype were lower in ischemic stroke patients than those observed in the control group (4.0% vs. 9.9%, OR=0.38, P=0.0046), and it were associated with the incidence of ischemic stroke in the multivariate analysis (OR=0.43, P=0.025). Genotypic analysis revealed that ischemic stroke patients with type 2 diabetes displayed a great lower prevalence of the Pro/Ala genotype (2.3%) than controls (9.9%) (OR=0.21, P=0.0047). And Pro/Ala genotype of type 2 diabetes patients with ischemic stroke were lower than type 2 diabetes patients without ischemic stroke (2.3% vs. 8.5%, OR=0.25, P=0.0321), however the significant association with ischemic stroke was not detected in the multivariate analysis (OR=0.27, P=0.051). These results suggest that the Pro/Ala genotype of PPAR-gamma2 Pro12Ala polymorphism may be associated with reduced risk for ischemic stroke, and the possibility that it might have a protective effect for ischemic stroke with type 2 diabetes.
    [Abstract] [Full Text] [Related] [New Search]